Advancis Pharmaceutical Corp.
This article was originally published in Start Up
Advancis Pharmaceutical Corp. is tackling antibiotic resistance with pulsed dosing technology that delivers repetitive bursts of anti-infective medications--both existing drugs and NCEs--in an attack pattern that denies microorganisms the chance to regroup between doses. This approach promises to work with lower total dosages and shorter durations of therapy, reducing side effects and aiding patient compliance.
You may also be interested in...
CombinatoRx's platform screens combinations of known drugs to find pairs that could deliver a one-two punch to diseases such as cancer and rheumatoid arthritis.
Paths to commercialization are uncertain in nutrigenomics, an emerging science which seeks to identify gene-food interactions that differ among subpopulations and between individuals and to personalize diets to prevent disease.
NutraGenomics Inc. is using a systems approach to identify diet-responsive genes and SNPs involved in chronic diseases such as Type 2 diabetes, obesity, atherosclerosis, and certain cancers, using proprietary mouse models to examine dietary effects on genes, proteins, transcription, and metabolism.